Celgene Corp (CELG) 147.01 $CELG
Final Glance: Biotechnology companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Early Glance: Biotechnology companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Earnings Roundup: Celgene's Rock-Solid Quarter Offers Opportunity
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Celgene is one of the most prolific deal makers in the biotech industry, inking dozens of collaborations with emerging biotechs working on the next big thing in medicine. Celgene's collaborations aim to expand upon an already-impressive...
After Yesterday's Rally of 2.75% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Rises 2.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Could Celgene Beat the Biotech Slide?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
Last Thursday, Celgene 's first quarter earnings call left the market with mixed emotions. Adjusted earnings per share of $1.67 beat estimates by just $0.02. Revenue grew 18.5% on year to $1.73 billion, $40 million less than the Street was...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Tweet of the Week: Drugmakers Can't Get a Second Drug Approved
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
This week's tweet of the week comes from Frank David, who points out a fact he learned in an article by Matthew Herper: Over half of companies that got a drug approved by the FDA from 1950 to 2011 did so only once. In the following video, senior...
Final Glance: Biotechnology companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Biotech Stock Roundup: Gilead's Sovaldi Shines, Biogen & Alexion Up Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 30, 9:55AM CDT
Gilead's (GILD) Sovaldi remained in the limelight with sales blowing past expectations.
Early Glance: Biotechnology companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Earnings Roundup: Celgene's Rock-Solid Quarter Offers Opportunity
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Celgene is one of the most prolific deal makers in the biotech industry, inking dozens of collaborations with emerging biotechs working on the next big thing in medicine. Celgene's collaborations aim to expand upon an already-impressive...
After Yesterday's Rally of 2.75% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Rises 2.75% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Apr 29, 3:45PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $142.10 to a high of $148.00. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $144.95 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Could Celgene Beat the Biotech Slide?
Cory Renauer, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
Last Thursday, Celgene 's first quarter earnings call left the market with mixed emotions. Adjusted earnings per share of $1.67 beat estimates by just $0.02. Revenue grew 18.5% on year to $1.73 billion, $40 million less than the Street was...
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Apr 28, 10:16AM CDT
Shares of Gilead Sciences (GILD) are higher today after it was reported that the biopharmaceutical company had a nine day winning streak end last week but it continues to outperform other big biotech stocks like Amgen (AMGN), Celgene (CELG) and...
Biotech M&A is MIA
at The Street - Mon Apr 28, 6:29AM CDT
Healthcare M&A activity is booming but expensive, risky biotech stocks are left on the sidelines.
Tweet of the Week: Drugmakers Can't Get a Second Drug Approved
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
This week's tweet of the week comes from Frank David, who points out a fact he learned in an article by Matthew Herper: Over half of companies that got a drug approved by the FDA from 1950 to 2011 did so only once. In the following video, senior...
